These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16388913)

  • 1. Reversal of supersensitive striatal dopamine D1 receptor signaling and extracellular signal-regulated kinase activity in dopamine-deficient mice.
    Kim DS; Palmiter RD; Cummins A; Gerfen CR
    Neuroscience; 2006; 137(4):1381-8. PubMed ID: 16388913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
    Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase.
    Gerfen CR; Miyachi S; Paletzki R; Brown P
    J Neurosci; 2002 Jun; 22(12):5042-54. PubMed ID: 12077200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences between dorsal and ventral striatum in Drd1a dopamine receptor coupling of dopamine- and cAMP-regulated phosphoprotein-32 to activation of extracellular signal-regulated kinase.
    Gerfen CR; Paletzki R; Worley P
    J Neurosci; 2008 Jul; 28(28):7113-20. PubMed ID: 18614680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation.
    Chartoff EH; Marck BT; Matsumoto AM; Dorsa DM; Palmiter RD
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10451-6. PubMed ID: 11517332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson's disease.
    Gerfen CR
    Neuroscientist; 2003 Dec; 9(6):455-62. PubMed ID: 14678578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D1 receptor regulation of preprotachykinin-A gene by extracellular signal-regulated kinase pathway in striatal cultures.
    Sin M; Michelhaugh SK; Bannon MJ
    Neuroreport; 2008 Jan; 19(2):187-91. PubMed ID: 18185106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial topography and cell-type specific regulation of the ERK pathway by dopaminergic agonists in the mouse striatum.
    Gangarossa G; Perroy J; Valjent E
    Brain Struct Funct; 2013 Mar; 218(2):405-19. PubMed ID: 22453353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
    Cerovic M; Bagetta V; Pendolino V; Ghiglieri V; Fasano S; Morella I; Hardingham N; Heuer A; Papale A; Marchisella F; Giampà C; Calabresi P; Picconi B; Brambilla R
    Biol Psychiatry; 2015 Jan; 77(2):106-15. PubMed ID: 24844602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.
    Dunah AW; Sirianni AC; Fienberg AA; Bastia E; Schwarzschild MA; Standaert DG
    Mol Pharmacol; 2004 Jan; 65(1):121-9. PubMed ID: 14722243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice.
    Santini E; Alcacer C; Cacciatore S; Heiman M; Hervé D; Greengard P; Girault JA; Valjent E; Fisone G
    J Neurochem; 2009 Feb; 108(3):621-33. PubMed ID: 19187092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function.
    Espadas I; Darmopil S; Vergaño-Vera E; Ortiz O; Oliva I; Vicario-Abejón C; Martín ED; Moratalla R
    Neurobiol Dis; 2012 Dec; 48(3):271-81. PubMed ID: 22820144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tyrosine phosphatase Shp-2 interacts with the dopamine D(1) receptor and triggers D(1) -mediated Erk signaling in striatal neurons.
    Fiorentini C; Mattanza C; Collo G; Savoia P; Spano P; Missale C
    J Neurochem; 2011 Apr; 117(2):253-63. PubMed ID: 21272002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M; Landry E; Lévesque D; Rouillard C
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative changes in Galphaolf protein levels, but not D1 receptor, alter specifically acute responses to psychostimulants.
    Corvol JC; Valjent E; Pascoli V; Robin A; Stipanovich A; Luedtke RR; Belluscio L; Girault JA; Hervé D
    Neuropsychopharmacology; 2007 May; 32(5):1109-21. PubMed ID: 17063155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.